Artificial blood business for human transfusion

• Development of red blood cells (RBC) for human transfusion from human immortalized red blood cell progenitors
• Development of artificial blood through genetic transformation and mass production using animals (e.g., pigs or cows)
• Global Artificial Blood Market is estimated to reach $10.73 billion by 2025 with 20% CAGR (source: Variant Market Research) projected to reach $30 billion by 2033
• RedGene is aiming to reach the estimated cultured RBC market sale at about $300 million in 2033.